Rejuvenate Bio Company
Rejuvenate Bio has developed a cardio-protective gene therapy that holds the promise of stopping the progression of MVD. We are preparing to run a pilot study in dogs with MVD.
Founded Date:
2017
Total Funding:
17.1M
Employee Number:
51-100
Funding Status:
Seed
Number Of Exists:
11-50
Technology:
Others
Last Funding Type:
Venture
Investors Number:
3
Last Funding Date:
Apr 27, 2021
Industry:
Gene therapy, PharmTech
Headquarters:
San Diego, California, United States